A test that has been available only to those who could afford it will become free
In a country where breast cancer rates continue to climb, Brazil has taken a quiet but consequential step toward equity in medicine: the public health system will now offer free genetic testing for BRCA1 and BRCA2 mutations, bringing a tool once reserved for those who could pay thousands of reais into the hands of any woman who needs it. The decision, formalized by official decree and backed by the national health commission's review of clinical evidence, reflects a broader reckoning with the idea that knowledge of one's own biological risk should not be a privilege. Within 180 days, a test that can reshape a family's relationship with cancer — guiding treatment, prompting prevention, and alerting relatives before disease takes hold — will be freely available through Brazil's public network.
- Women carrying BRCA1 or BRCA2 mutations face 60 to 80 percent higher odds of developing breast cancer, yet until now the test to detect these mutations cost between R$1,000 and R$3,000 — pricing out the majority of Brazilians who rely on public health care.
- Brazil's national health commission formally approved the test for public coverage after weighing clinical evidence, and the Health Ministry issued a decree setting a 180-day deadline for the public network to make it available nationwide.
- The test serves a double purpose: for women already diagnosed with breast cancer, it guides doctors toward targeted therapies; for their relatives, a positive result becomes an early warning that can trigger preventive monitoring or surgery before any cancer develops.
- The announcement arrives as breast cancer cases rise across Brazil — Mato Grosso do Sul alone recorded 814 cases in 2024 — making the expansion of precision screening tools a matter of urgent public health.
- The 180-day rollout will stress-test the public system's capacity for genetic sequencing infrastructure, trained personnel, and equitable geographic access, with the promise of universal availability only as strong as the network built to deliver it.
Brazil's Health Ministry announced this week that the public health system will begin offering free genetic testing for hereditary breast cancer — a test that currently costs between one thousand and three thousand reais in private clinics. The screening looks for mutations in the BRCA1 and BRCA2 genes, which are responsible for repairing DNA damage. When these genes carry mutations, a woman's risk of developing breast cancer rises by 60 to 80 percent above the general population. An official decree published in the government gazette set a timeline of up to 180 days for the public network to make the test available across the country.
The test will initially be offered to women already diagnosed with breast cancer, where it serves two purposes at once. For the patient, genetic information helps doctors select the most effective treatment, including therapies designed to target specific mutations. For her family, the results reveal who else may carry the same alteration — a warning signal that can prompt preventive action before any cancer develops, from more frequent imaging to, in some cases, preventive surgery.
The decision followed a review by Conitec, the national commission that evaluates new treatments and diagnostics for the public health service. The test has carried cultural weight since 2013, when Angelina Jolie publicly disclosed her BRCA1 mutation and her choice to undergo a preventive mastectomy, bringing global attention to the genetic roots of some breast cancers. In Brazil, where cases have been rising — Mato Grosso do Sul recorded 814 in 2024, the highest rate in the central-west region — the move signals a meaningful shift toward precision medicine in the public sector.
The 180-day window ahead will test the system's real capacity: building genetic sequencing infrastructure, training staff to interpret results, and ensuring that women across the country can actually reach the test. For now, the announcement stands as a commitment that within six months, what was once available only to those who could afford private care will be free for anyone in Brazil's public health system.
Brazil's Health Ministry announced this week that the public health system will begin offering free genetic testing for hereditary breast cancer, a test that currently costs between one thousand and three thousand reais in private clinics. The test screens for mutations in the BRCA1 and BRCA2 genes, which are responsible for repairing damage to DNA. When these genes carry mutations, the risk of developing breast cancer rises sharply—women with these alterations face between 60 and 80 percent higher odds of the disease than the general population. The announcement came by way of an official decree published in the government gazette, with a timeline of up to 180 days for the public health network to make the test available across the country.
The test will initially be offered to women already diagnosed with breast cancer, where it serves two purposes at once. For the patient herself, the genetic information helps doctors choose the most effective treatment, including targeted therapies designed to work against specific genetic mutations. For her family members, the results can reveal who else carries the same mutation and therefore faces elevated risk. This matters because these genetic alterations can be inherited, meaning a positive result in one woman's test becomes a warning signal for her relatives.
The decision to add this technology to Brazil's public system came after review by Conitec, the national commission responsible for evaluating new treatments and diagnostic tools for the health service. The commission weighed the clinical evidence and determined the test met the criteria for public coverage. For families with a history of breast cancer, the implications are significant. Relatives identified as carriers can pursue preventive strategies before any cancer develops—more frequent imaging scans, regular medical monitoring, and in some cases, preventive surgery to remove breast tissue at high risk.
The test has become increasingly prominent in public consciousness since 2013, when actress Angelina Jolie disclosed that she carried a BRCA1 mutation and chose to have a preventive mastectomy given her family's cancer history. That revelation brought international attention to the genetic basis of some breast cancers and the possibility of intervening before disease takes hold. In Brazil, where breast cancer rates have been climbing—Mato Grosso do Sul recorded 814 cases in 2024, the highest rate in the central-west region—expanding access to this screening tool represents a significant shift toward precision medicine in the public sector.
The 180-day window ahead will test the health system's capacity to implement the test at scale. Success depends on establishing the infrastructure to perform genetic sequencing across the country's public network, training staff to interpret results, and ensuring that women who need the test can actually access it. For now, the announcement stands as a commitment: within six months, a test that has been available only to those who could afford private care will become free for anyone in Brazil's public health system.
Notable Quotes
The genetic information helps doctors choose the most effective treatment, including targeted therapies designed to work against specific genetic mutations— Health Ministry announcement
The Hearth Conversation Another angle on the story
Why does this matter for women who already have breast cancer? Isn't the diagnosis itself the urgent problem?
The diagnosis is urgent, yes. But knowing whether the cancer is driven by a BRCA mutation changes how doctors treat it. Some drugs work specifically against those mutations. And it tells you whether your sister or daughter is at risk before they get sick.
So it's not just about the individual patient.
Not at all. One woman's test result becomes a map for her whole family. If she carries the mutation, her relatives can start preventive screening or even preventive surgery. That's the real power—catching it before it happens.
The test costs up to three thousand reais privately. That's a barrier for most people.
Exactly. Right now, only women with money can know if they're at genetic risk. This makes it free. But the real test is whether the public system can actually deliver it in 180 days across the whole country.
What could go wrong in that rollout?
Training enough people to do the sequencing, getting the equipment in place, making sure rural areas aren't left behind. It's one thing to announce a policy. It's another to make it real for a woman in a small town.
Has this test changed how people think about cancer prevention?
The Angelina Jolie moment in 2013 showed people that you could act before cancer appears. That's a different mindset—not waiting for disease, but intercepting risk. This policy extends that possibility to people who couldn't afford it before.